An observational study in Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy and Sarcopenia, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by University Hospital, Ghent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium — 13 open to participants now, 19 under way, 5 of them phase 3. Diabetes Mellitus, Type 2 · Belgium.
Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, this one is the 15th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2023, is one of 18 observational ones, reaches primary completion later than 0 of the 18 other live ones, and was the 138th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 8 more countries
Ages 10–17
Novo Nordisk A/S · Sites in Belgium, United States, Argentina and 16 more countries
Ages 18+
University Hospital, Ghent · Sites in Belgium
Ages 40–85 · Healthy volunteers
Universiteit Antwerpen · Sites in Belgium
Ages 60+
Boehringer Ingelheim · Sites in Belgium, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 79 · Phase 4 10
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 145 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 504 across the 131 interventional studies, 759 across the 18 observational. Of the 126 that completed or were terminated, 69 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 149 have an industry lead sponsor. The 10 most frequent:
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
University Hospital, Ghent has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04993482University Hospital, Ghent24-hour Movement Behaviors Among Type 2 Diabetes Mellitus Patients | 2026-12-01 |
| NCT07257822KU LeuvenThe Digital Diabetes Patient Reminder (DIPAR) Tool For Adults With Type 2 Diabetes | 2027-06 |
| NCT07786194Universiteit AntwerpenImprovement Through Movement - Balance Control and Somatosensory Function in People With Diabetes Mellitus Type 2 | 2027-07-31 |
| NCT06734546Hasselt UniversityThe Effect of Exercise on the Brain in Type 2 Diabetes | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate muscle fiber type composition in people with type 2 diabetes mellitus (T2DM) with a common complication of T2DM: diabetic peripheral neuropathy (DNP), specifically diabetic sensorimotor polyneuropathy. Researchers will also look into factors related to DNP: inflammation, the use of energy in the cell, nerve function and the tiny blood vessels in the muscle.
The main question it aims to answer is: Are there differences in muscle fiber type composition between persons with T2DM with and without DNP, in comparison to sex and age-matched healthy peers?
Participants will partake in the following tests:
Researchers will compare (1) patients with T2DM with DNP, (2) patients with T2DM without DNP, and (3) healthy persons to see if there are differences in muscle fiber type composition
Participants will be recruited through the Ghent University Hospital, diabetes educators and podologists.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants:
Persons with T2DM:
Exclusion Criteria:
All participants:
Healthy controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
type 2 diabetes with diabetic neuropathy
Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry
type 2 diabetes without diabetic neuropathy
Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry
healthy controls
Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry
Fasting blood samples will be obtained.
Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
A qPCT scan of the calf will be performed.
Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
A 15-minute resting ECG will be performed.
Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.
Differences in muscle fiber type composition in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in muscle fiber type distribution, percentage and cross-sectional area will be evaluated through myosin heavy chain (MHC) immunostaining of the muscle specimen.
Time frame: At enrollment
Differences in nerve conduction velocity in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls
Nerve conduction velocity will be examined through EMNG examination to examine neuromotor function
Time frame: At enrollment
Differences in capillarization in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Capillarization will be examined through histological examination of the muscle specimen using Ulex europaeus I (UEA-I) staining.
Time frame: At enrollment
Differences in electron microscopic properties assessing mitochondrial function in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls
Mitochondrial function will be examined through electron microscopy of the muscle specimen.
Time frame: At enrollment
Differences in maximal force in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Maximal force will be evaluated using mechanography through multiple one leg hopping.
Time frame: At enrollment
Differences in maximal power in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Maximal power will be evaluated using mechanography through the single two leg jump.
Time frame: At enrollment
Differences in functional muscle strength in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Functional strength will be examined using mechanography through the chair rising test and heel rise test.
Time frame: At enrollment
Differences in physical activity levels in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in the lifestyle factor physical activity will be examined through the International Physical Activity Questionnaire (IPAQ) - Long Form).
Time frame: At enrollment
Differences in food intake in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in the lifestyle factor food intake will be examined through a food frequency questionnaire.
Time frame: At enrollment
Differences in lifestyle factors in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in lifestyle factors smoking and ethyl consumption will be examined through non-official questionnaires.
Time frame: At enrollment
Differences in muscle density in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in muscle density will be evaluated through pQCT of the calf.
Time frame: At enrollment
Differences in bone density in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in bone density will be evaluated through pQCT of the calf.
Time frame: At enrollment
Differences in heart rate variability in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Heart rate variability will be examined through a 15-minute resting ECG.
Time frame: At enrollment
Differences in interleukin 6 (IL-6) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in inflammation will be evaluated through blood analysis of IL-6.
Time frame: At enrollment
Differences in tumor necrosis factor alpha (TNFα) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in inflammation will be evaluated through blood analysis of TNFα.
Time frame: At enrollment
Differences in C-reactive protein (CRP) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in inflammation will be evaluated through blood analysis of CRP.
Time frame: At enrollment
Differences in mononuclear cell numbers in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Differences in inflammation will be evaluated through flow cytometry to assess mononuclear cell numbers.
Time frame: At enrollment
Differences in protein concentrations for AMPK and PGC-1α in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls
Differences in protein concentrations for 5' adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α) will be examined using western blotting (on the muscle sample)
Time frame: At enrollment
Differences in citrate synthase activity in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls
Citrate synthase activity will be examined using an activity assay (on the muscle sample).
Time frame: At enrollment
Differences in succinate dehydrogenase B (SDHB) expression in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls
SDHB expression will be examined through immunohistochemical staining for SDHB of the muscle specimen.
Time frame: At enrollment
Differences in vascular endothelial growth factor (VEGF) concentrations in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.
Vascular endothelial growth factor concentrations will be examined through blood analysis.
Time frame: At enrollment
Plan to share: Yes — After publication, anonymous individual participant data can be made available to other researchers upon request.
Supporting information: Study protocol, Informed consent form
Time frame: After publication
Access criteria: Upon request to corresponding author
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Nov 2025, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.